STOCK TITAN

Olema Pharmaceuticals: BVF reports roughly 9.8% stake

A 9.99% ownership blocker limits exercise to 3,643,838 of the 6,373,040 shares underlying reported pre-funded warrants.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. (OLMA) is the issuer in an amended ownership report by BVF Partners LP and affiliated reporting persons, who report 8,939,731 shares beneficially owned, or approximately 9.8%. The reported amount reflects holdings attributed through affiliated funds and managed accounts, and related reporting persons report some of the same shares. Biotechnology Value Fund separately reports 5,946,981 shares, or approximately 6.6%.

The reporting persons and one Partners Managed Account report holding pre-funded warrants underlying 6,373,040 shares. Each warrant is immediately exercisable for one share at $0.0001 per share, subject to a 9.99% ownership blocker that limits currently exercisable shares to 3,643,838. Gorjan Hrustanovic resigned from Olema’s Board, Compensation Committee and Science and Technology Committee effective October 14, 2026; the resignation was not the result of disagreement with Olema on its operations, policies or practices. The reporting persons report no securities transactions during the prior 60 days.

Filing Explained

The amendment reports that former director Gorjan Hrustanovic has options exercisable within 60 days for 183,645 shares, awarded for no consideration, and an agreement requires him to transfer to BVF Partners any economic benefit received if he sells them.

Shares beneficially owned 8,939,731 shares Reported by BVF Partners LP; approximately 9.8%
Shares beneficially owned 5,946,981 shares Reported by Biotechnology Value Fund; approximately 6.6%
Shares underlying pre-funded warrants 6,373,040 shares Held by the reporting persons and one Partners Managed Account
Shares currently exercisable under the blocker 3,643,838 shares Limited by the pre-funded warrant ownership blocker
Pre-funded warrant ownership blocker 9.99% Maximum ownership after exercise, including attribution parties
Shares outstanding 87,497,607 shares As of August 6, 2026
Shares underlying Gorjan Hrustanovic’s stock options 183,645 shares Options exercisable within 60 days
Pre-funded warrant exercise price $0.0001 per share Each warrant is exercisable into one share
Pre-Funded Warrants financial
"held Pre-Funded Warrants exercisable for an aggregate of 6,373,040 Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Pre-Funded Warrants Blocker financial
"the “Pre-Funded Warrants Blocker”"
beneficial ownership regulatory
"as to beneficial ownership of any Shares owned by another Reporting Person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
aggregate cost basis financial
"The aggregate cost basis of the 2,655,977 Shares directly beneficially owned by BVF"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the exercise limit for OLMA pre-funded warrants?

The holders may not exercise a warrant to the extent doing so would cause them and their attribution parties to own more than 9.99% of shares outstanding immediately after exercise. Each warrant is immediately exercisable for one share at $0.0001 per share, and the blocker limits currently exercisable shares to 3,643,838 of 6,373,040 underlying shares.

Why did Gorjan Hrustanovic resign from Olema’s board?

Gorjan Hrustanovic resigned from Olema’s Board and its Compensation and Science and Technology committees effective October 14, 2026. The stated reason was not a disagreement with Olema on its operations, policies or practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates





68062P106

(CUSIP Number)
JAMES KRATKY
BVF PARTNERS L.P., 44 Montgomery St., 40th Floor
San Francisco, CA, 94104
415-525-8830


KEN SCHLESINGER & IAN ENGORON
OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
New York, NY, 10019
212-451-2300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
10/14/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:10/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:10/16/2026
Hrustanovic Gorjan
Signature:/s/ Hrustanovic Gorjan
Name/Title:Hrustanovic Gorjan
Date:10/16/2026

Keep reading